Polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 7, 2005, Pages 861-866

  Lainka, Elke ^a,d   Hershfield, Michael S ^b   Santisteban, Ines ^b   Bali, Pawan ^b   Seibt, Annette ^a   Neubert, Jennifer ^a   Friedrich, Wilhelm ^c   Niehues, Tim ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PEGADEMASE; TUMOR NECROSIS FACTOR ALPHA;

ADENOSINE DEAMINASE DEFICIENCY; APOPTOSIS; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BONE MARROW TRANSPLANTATION; CASE REPORT; CAUSE OF DEATH; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PURINE METABOLISM; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REACTIVATION;

ADENOSINE DEAMINASE; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; ENZYMES, IMMOBILIZED; FEMALE; HUMANS; INFANT; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; POLYETHYLENE GLYCOLS; PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS; T-LYMPHOCYTE SUBSETS;

EID: 22244455374     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.7.861-866.2005     Document Type: Article

References (25)

1. Aldrich, M. D., W. Chen, M. R. Blackburn, H. Martinez-Valdez, S. K. Datta, and R. E. Kellems. 2003. Impaired germinal center maturation in adenosine deaminase deficiency. J. Immunol. 171:5562-5570.
2. Arredondo-Vega, F. X., I. Santisteban, S. Daniels, S. Toutain, and M. S. Hershfield. 1998. Adenosine deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am. J. Hum. Genet. 63:1049-1059.
3. Arrendondo-Vega, F. X., I. Santisteban, L. D. Notarangelo, J, El Dahr, R. Buckley, C. Roifman, et al. 1998. Seven novel mutations in the adenosine deaminase (ADA) gene in patients with severe and delayed onset combined immunodeficiency: G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del. Mutations in brief no. 142. Hum. Mut. 11:482. [Online.]
4. Arredondo-Vega, F. X., I. Santisteban, E. Richard, P. Bali, M. Koleilat, M. Loubser, et al. 2002. Adenosine deaminase deficiency with mosaicism for a "second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood 99:1005-1013.
5. Benveniste, P., and A. Cohen. 1995. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA 92:8373-8377.
6. Bollinger, M. E., F. X. Arredondo-Vega, I. Santisteban, K. Schwarz, M. S. Hershfield, and H. M. Lederman. 1996. Hepatic dysfunction as a complication of adenosine deaminase deficiency. N. Engl. J. Med. 334:1367-1371.
7. Chaffee, S., A. Mary, E. R. Stiehm, D. Girault, A. Fischer, and M. S. Hershfield. 1992. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Investig. 89:1643-1651.
8. Chen, R., L. Lowe, J. D. Wilson, E. Crowther, K. Tzeggai, J. E. Bishop, et al. 1999. Simultaneous quanlification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin. Chem. 45:1693-1694.
9. Chun, J. D., N. Lee, R. H. Kobayashi, S. Chaffee, M. S. Hershfield, and E. R. Stiehm. 1993. Suppression of an antibody to adenosine deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase. Ann. Allergy 70:462-466.
10. Comans-Bitter, W. M., R. de Groot, R. van den Beemd, H. J. Neijens, W. C. J. Hop, K. Groeneveld, et al. 1997. Immunophenotyping of blood lymphocytes in childhood, reference values for lymphocyte subpopulations. J. Pediatr. 130:388-393.
11. Cowan, M. J., W. Smith, and A. J. Ammann. 1989. Interleukin 2 responsive lymphocytes in patients with adenosine deaminase deficiency. Clin. Immunol. Immunopathol. 53:59-67.
12. Genini, D., I. Budihardjo, W. Plunkett, X. Wang, C. J. Carrera, H. B. Cottam, et al. 2000. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J. Biol. Chem. 275:29-34.
13. Giblett, E. R., J. E. Anderson, F. Cohen, B. Pollara, and H. J. Meuwissen. 1972. Adenosine deaminase deficiency in two patients with severely impaired immunity. Lancet ii:1067-1069.
14. Hershfield, M. S. 1997. Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA), p. 145-154. In J. M. Harris and S Zalipsky (ed.), Poly(ethylene glycol) chemistry and biological applications. American Chemical Society, Washington, D.C.
15. Hershfield, M. S. 2004. Combined immune deficiencies due to purine enzyme defects, p. 480-504. In E. R. Stiehm, H. D. Ochs, and J. Winkelstein (ed.). Immunologic disorders in infants and children, 5th ed. The W. B. Saunders Co., Philadelphia, Pa.
16. Hershfield, M. S., R. H. Buckley, M. L. Greenberg, A. L. Melton, R. Schiff, C. Hatem, et al. 1987. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N. Engl. J. Med. 316: 589-596.
17. Hershfield, M. S., and B. S. Mitchell. 2001. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency, p. 2585-2611. In C. R. Scriver et al. (ed.), Metabolic and molecular bases of inherited disease, vol. 11. 8th ed. McGraw-Hill Book Co., New York, N.Y.
18. Hirschhorn, R. 1993. Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency. Pediatr. Res. 33:S35-S41.
19. Hirschhorn, R. 1999. Immunodeficiency disease due to deficiency of adenosine deaminase, p. 121-139. In H. D. Ochs et al. (ed.), Primary immunodeficiency diseases, a molecular and genetic approach. Oxford University Press, Oxford, United Kingdom.
20. Niehues, T., T. W. McCloskey, J. Ndagijimana, G. Horneff, V. Wahn, and S. Pahwa. 2001. Apoptosis in T-lymphocyte subsets in human immunodeficiency virus-infected children measured immediately ex vivo and following in vitro activation. Clin. Diagn. Lab. Immunol. 8:74-78.
21. Niehues, T., J. Ndagijimana, G. Horneff, and V. Wahn. 1998. CD28 expression in pediatric human immunodeficiency virus infection. Pediatr. Res. 44:265-268.
22. Ochs, H. D., R. H. Buckley, R. H. Kobayashi, A. L. Kobayashi, R. U. Sorensen, S. D. Douglas, et al. 1992. Antibody responses to bacteriophage φX174 in patients with adenosine deaminase deficiency. Blood 80:1163-1171.
23. Thompson, L. F., C. J. Van De Wiele, A. B. Laurent, S. W. Hooker, J. G. Vaughan, H. Jiang, et al. 2000. Metabolites from apoptotic thymocytes inhibit thymopoiesis in adenosine deaminase-deficient fetal thymic organ cultures. J. Clin. Investig. 106:1149-1157.
24. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317.
25. Weinberg, K., M. S. Hershfield, J. Bastian, D. Kohn, L. Sender, R. Parkman, et al. 1993. T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. J. Clin. Investig. 92:596-602.